HSHelène Schulte

Helène Schulte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helène Schulte has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Alf Sollevi

    2 shared publications
  • Märta Segerdahl

    2 shared publications
  • A. Sollevi

    Center for Surgical Sciences, Unit for Anaesthesia, Department of Anaesthesia and Intensive Care, Huddinge University Hospital, Stockholm, Sweden

    1 shared publication
  • Lars Arendt-Nielsen

    Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI) Center, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark

    1 shared publication
  • M. Segerdahl

    Center for Surgical Sciences, Unit for Anaesthesia, Department of Anaesthesia and Intensive Care, Huddinge University Hospital, Stockholm, Sweden

    1 shared publication
  • Thomas Graven-Nielsen

    Center for Neuroplasticity and Pain (CNAP), Department of Health Science and Technology, Faculty of Medicine Aalborg University Aalborg Denmark

    1 shared publication

Latest Publications

  • Dose-dependent effects of morphine on experimentally induced cutaneous pain in healthy volunteers

    by Helène Schulte, Alf Sollevi, Märta Segerdahl

    This study examines the dose dependent analgesic effects of two doses of morphine and a single dose of alfentanil on experimentally induced cutaneous pain. In 16 healthy volunteers pain was induced by a skin burn injury and by continuous electrical skin stimulation. Mechanical pain thresholds (PT, von Frey filament), area of secondary hyperalgesia (SH) and 'wind-up like pain' upon repetitive stimulation (40-g load, 3Hz, 30s) were assessed. Analgesic effects on these pain parameters were tested at steady-state IV infusions of morphine, 50% (plasma concentration 15ng/ml) and 100% (plasma concentration 30ng/ml) of maximal tolerable dose to be given to healthy volunteers, and with an effective dose of alfentanil (plasma concentration 70ng/ml). All effects were compared to active placebo, midazolam infusion (20microg/kg for 10min). Alfentanil significantly diminished the SH area in the burn injury model as well as in the electrical pain model. Additionally, alfentanil increased PT several fold in both models. The high dose of morphine showed a similar analgesic response pattern as alfentanil even though the effects were only statistically significant in the electrical pain model. The low dose of morphine as well as placebo did not affect these pain parameters. 'Wind-up like pain' was not influenced by any of the given drugs. In conclusion, the present study clearly indicates dose dependent effects of morphine on experimentally induced cutaneous pain. The high dose of morphine (30ng/ml) was approximately equianalgesic to the administered alfentanil dose (70ng/ml).


  • The Synergistic Effect of Combined Treatment with Systemic Ketamine and Morphine on Experimentally Induced Windup-Like Pain in Humans

    by Helène Schulte, Alf Sollevi, Märta Segerdahl

    D MO (10 μg · kg−1 · min−1; 10 min) alone and in combination, as well as placebo (saline; 10 min), were studied in a randomized, crossover, double-blinded design. The area of secondary hyperalgesia (SH) for mechanical stimulation was diminished by KET as compared with placebo. Mechanical pain thresholds were increased severalfold with KET and with KET plus MO, both in the primary hyperalgesic (PH; burn injury) and SH area. MO infusion showed no effect on the SH area or pain threshold. Windup-like pain was evaluated by continuous assessment on a visual analog scale during 30 s of repetitive stimulation (40-g load at 3 Hz) and analyzed as a sum of pain scores. The combined treatment (KET plus MO) almost abolished windup-like pain both in the PH and the SH areas, an effect that was not present with monotherapy with KET or MO. This study provides experimental support for a positive analgesic interaction between an N-methyl-D-aspartate receptor antagonist and an opioid on central summation of pain....


  • Pharmacological modulation of experimental phasic and tonic muscle pain by morphine, alfentanil and ketamine in healthy volunteers

    by H. Schulte, T. Graven‐Nielsen, A. Sollevi, Y. Jansson, L. Arendt‐Nielsen, M. Segerdahl

    Background:  Muscle pain is a major clinical problem but the underlying mechanisms and its pharmacological modulation need further investigation. This study on 15 volunteers evaluates if two experimental muscle pain models are sensitive to µ‐receptor agonists and to an N‐methyl‐D‐aspartate (NMDA)‐receptor antagonist.Methods:  In the left tibialis anterior, intramuscular electrical (IMES) pain thresholds were determined for single (SPTmuscle) and five (RPTmuscle) repeated stimuli. Also pain to suprathreshold stimulation at 150% of RPTmuscle, 10 s, was assessed on a visual analog scale (VAS) as AUCimes (area under the VAS curve). In the right TA muscle, pain intensity on infusion of 0.5 ml of hypertonic saline, 5% (AUCsaline) and pain distribution indicated as local and referred were evaluated. Pain variables were assessed before, during and after intravenous infusions of morphine (10 µg kg−1 min−1, 10 min), alfentanil (target‐controlled infusion, plasma concentration; 60 ng ml−1, 60 min) and ketamine (10 µg kg−1 min−1, 60 min). All data were normalized to baseline pain values (before drug infusions were initiated) and compared with placebo (midazolam, 2 µg kg−1 min−1, 10 min).Results:  SPTmuscle increased (log mean values ± SD, mA) with morphine (0.11 ± 0.17, P < 0.05), alfentanil (0.28 ± 0.24, P < 0.001) and ketamine (0.19 ± 0.18, P < 0.01) as compared with placebo (−0.03 ± 0.12). Alfentanil and ketamine also increased RPTmuscle (0.25 ± 0.21, P < 0.01 and 0.21 ± 0.19, P < 0.05, respectively) as compared with placebo (0.00 ± 0.17). Pain to IMES (AUCimes) was reduced (median values [25th−75th percentiles], cm × s) by alfentanil and ketamine (−19.7 [−14.6 – −29.6] and−12.8 [−8.3 – −27.8], P < 0.05, respectively) vs. placebo (−0.8 [1.6 – −12.3]). Similar drug effects were seen when pain to infusion of hypertonic saline (AUCsaline) was assessed (alfentanil:−388 [−99 – −677] and ketamine:−326 [−227 – −573], P < 0.05 compared with placebo: 150 [449–−240]). Ketamine also reduced the size of the local pain area (−58.4 [−21.2 – −176.1], < 0.05) as compared with placebo (−0.4 [70.6 – −13.4]). The frequency of referred pain was also lower when ketamine was given (3/13, P < 0.05) vs. placebo (9/14).Conclusion:  The study demonstrates that experimental muscle pain induced in humans by electrical stimulation and infusion of hypertonic saline is sensitive to pharmacological modulation similar to preclinical animal tests and clinical trials. The data suggest that these models can be valuable tools in analgesic drug development.